Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VACV tablets (Adults or pediatrics) or granules (pediatrics)
VACV or granules · 1 trial · 1 indication
Viral isolation/identification was conducted if the investigator (or subinvestigator) suspected HSV infection according to the relevant clinical symptoms (oral mucositis, skin infection, genital herpes, and pneumonia). If the result of viral isolation/identification was positive, the participant concerned was defined as a case of HSV infection. For reference, a virus deoxyribonucleic acid (DNA) identification (PCR) was simultaneously performed.
| Arm | Type | Description |
|---|---|---|
| VACV (256U87; valaciclovir hydrochloride) | EXPERIMENTAL | Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily. |
| Name | Type | Description |
|---|---|---|
| VACV tablets (Adults or pediatrics) or granules (pediatrics) | DRUG | A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor. |
Inclusion Criteria: * Patients who are planning to undergo hematopoietic stem cell transplantation, except cord blood transplantation. * Patients aged from 1 and above to under 65 at the time of informed consent. * Patients who can submit their voluntary written informed consent if they are 12 year...
VACV is an investigational small molecule developed by GSK plc for herpes simplex. It is being studied in a Phase 3 trial in Japan involving patients who have undergone hematopoietic stem cell transplantation. The trial enrolled 40 participants, including adults and pediatric patients aged 1 year and older.
VACV is developed by GSK plc, which trades under the ticker GSK. The company is responsible for the clinical development of this small molecule for herpes simplex.
VACV is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The completed trial, NCT01602562, studied VACV in hematopoietic stem cell transplantation patients with herpes simplex in Japan.
VACV has been studied in one completed Phase 3 trial, NCT01602562, titled Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients. The trial enrolled 40 participants in Japan and included patients aged 1 year and older with herpes simplex.
Yes, VACV is also known as VACV tablets for adults or pediatrics, and VACV granules for pediatrics. These refer to the same investigational product developed by GSK plc for herpes simplex.